A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies

B-Cell Lymphoma Clinical Trial

Official title:

An Open Label, Single-site, Dose-escalation Study Aiming to Evaluate the Efficacy and Safety of Anti-CD19 CAR-T Manufactured by OlyCAR Platform(OlyCAR-019) in the Treatment of Relapsed/ Refractory(r/r) B-Cell Malignancies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05932173
• Other study ID #: KM-PBC920
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: July 1, 2023
• Est. completion date: June 30, 2025

Study information

• Verified date: July 2023
• Source: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
• Contact: Sanbin Wang, Professor
• Phone: 13187424131
• Email: Sanbin1011[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It is a single-center, open-labeled, single-arm, non-randomized, investigator-initiated trial aiming to evaluate the efficacy and safety of anti-CD19 CAR-T manufactured by OlyCAR platform (OlyCAR-019) for CD19+ refractory/relapsed B-Cell malignancies.

Description:

OlyCAR is a novel CAR-T manufacturing system which allows to generate clinical-use CAR-T cells in short time. This study is going to evaluate the feasibility of CAR-T manufactured by OlyCAR platform in the treatment of B-Cell malignancies. The OlyCAR-019 cells will be infused by vein. Subjects will be followed for safety and efficacy up to 12 weeks. For those with a durable remission 12 weeks after infusion, the follow-up will last for at least 12 months for disease control.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: June 30, 2025
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 75 Years

Eligibility

Key Inclusion Criteria:

1. A definite diagnosis of relapsed/refractory B-cell malignancies;

2. Male or female, aged 2-75 years;

3. Confirmed detectable disease;

4. Expected survival time >12 weeks;

5. Eastern cooperative oncology group (ECOG) score is 0-2;

6. Adequate liver , kidney and cardiopulmonary function;

7. Women of childbearing age have negative blood pregnancy test before the start of the trial, and agree to take effective contraceptive measures during the trial until the last follow-up; male subjects with partners of childbearing potential agree to take effective contraceptive measures during the trial until the last follow-up;

8. Willingness to complete the informed consent process and to comply with study procedures and visit schedule.

Key Exclusion Criteria:

1. Presence of other concurrent active malignancy; People with severe mental disorders;

2. History of any of the following genetic disorders, such as Fanconi anemia, Schu-Day syndrome, Gerstmann syndrome, or any other known bone marrow failure syndrome;

3. Acute GVHD of grade II-IV or extensive chronic GVHD;

4. Grade III-IV heart failure or myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other clinically prominent heart disease within one year prior to enrollment;

5. The presence of any indwelling catheter or drainage (e.g., percutaneous nephrostomy, indwelling catheter, bile drainage, or pleural/peritoneal/pericardial catheter), except for patients who are permitted to use dedicated central venous catheters;

6. Human immunodeficiency virus (HIV) seropositivity; Hepatitis B surface antigen positive or hepatitis B core antibody positive, and HBV-DNA positive; Patients with hepatitis C (HCV-RNA quantitative test results positive); Or the presence of other serious active viral or bacterial infections or uncontrolled systemic fungal infections; Patients with severe history of allergy or allergic constitution;

7. A history of autoimmune diseases (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) leading to end-organ damage or requiring systemic immunosuppressive/systemic disease modulating drugs within the past 2 years; Had or is suffering from interstitial lung disease (e.g., pneumonia, pulmonary fibrosis);

8. Had undergone other clinical trials in the 4 weeks prior to participating in this trial;

9. Poor compliance due to physiological, family, social, geographical and other factors, unable to cooperate with the study protocol and follow-up plan;

10. For patients contraindicated with cyclophosphamide and fludarabine chemotherapy;

11. Subjects requiring systemic corticosteroid therapy (prednisone =5mg/ day or equivalent dose of another corticosteroid) or other immunosuppressive agents within 1 month after UCAR-T cell reinfusion, except for adverse events;

12. Receiving donor lymphocyte infusion within 6 weeks before enrollment;

13. Pregnant and lactating women;

14. Subjects with any other condition which the investigator considers unsuitable for inclusion in the study.

Related Conditions & MeSH terms

• B-Cell Leukemia
• B-Cell Lymphoma
• Leukemia, B-Cell
• Leukemia, Lymphocytic, Chronic, B-Cell

Intervention

Biological:
• Anti-CD19 Autologous CAR-T Cell Infusion
Autologous T cells modified with anti-CD19 ScFv expression and manufactured by OlyCAR platform

Locations

Country	Name	City	State
China	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China	Kunming	Yunnan

Sponsors (1)

Lead Sponsor	Collaborator
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events(AE) after infusion	The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included.	Up to 12 months after infusion
Primary	MTD	MTD will be determined based on DLTs observed during the first 28 days of study treatment.	Up to 28 days after infusion
Secondary	Overall Response Rate (ORR)	Overall Response Rate (ORR) is defined as the proportion of subjects achieving complete remission(CR) and partial response(PR).	Up to 3 months after infusion
Secondary	Progression-free survival(PFS)	Progression-free survival(PFS) refers to the time from cell infusion to the first assessment of tumor progression or death from any cause.	Up to 3 months after infusion